In a challenging year for biotechnology firms, PureTech Health PLC (PRTC) stock has touched a 52-week low, dipping to $16.81.

PureTech also has discovery and preclinical-stage candidates in oncology, including anti-Galectin-9 and Delta-1 antibodies for solid tumours. Image by Gerd Altmann from Pixabay Image ...

PureTech expects to announce topline results in mid-2021. This follows a phase 1 trial of the drug in March testing its safety, tolerabili ty and pharmacokinetic profile in several doses in ...

PureTech has presented data demonstrating high expression of galectin-9 across various solid tumor types and blood cancers and has found that, in several cancers, galectin-9 levels correlate with ...

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

These are two of the most undervalued wide-moat stocks that Morningstar’s analysts cover today. We sell different types of products and services to both investment professionals and individual ...

Check the time stamp on this data. Updated AI-Generated Signals for Puretech Health Plc (PRTC) available here: PRTC. Type a ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment ...

J.D., Entrepreneur-in-Residence at PureTech who is leading the Gallop Oncology work. "This milestone builds on the FDA’s recognition of LYT-200’s promise, including Orphan Drug designation for ...

(RTTNews) - Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LYT-200, a first-in-class ...

J.D., Entrepreneur-in-Residence at PureTech who is leading the Gallop Oncology work. "This milestone builds on the FDA’s recognition of LYT-200’s promise, including Orphan Drug designation for AML and ...